Jinhai Medical Technology Limited
今海醫療科技股份有限公司

(Incorporated in the Cayman Islands with members' limited liability)

(Stock Code: 2225)

SUPPLEMENTAL ANNOUNCEMENT IN RELATION TO ANNUAL REPORT 2025

Reference is made to the annual report of Jinhai Medical Technology Limited (the "**Company**", together with its subsidiaries, the "**Group**") for the year ended 31 December 2025 published on 24 April 2026 (the "**Annual Report**").

References are also made to the circular of the Company dated 8 December 2023, the share option scheme published by the Company dated 8 December 2023 (the "**Share Option Scheme**") and the poll results announcement of the Company dated 29 December 2023 in relation to the adoption of the Share Option Scheme, and the announcement of the Company dated 9 January 2024, the circular of the Company dated 29 January 2024 and the poll results announcement of the Company dated 19 February 2024 in relation to the grant of options under Share Option Scheme.

Unless the context otherwise requires, capitalised terms used in this announcement shall have the same meanings as those defined in the Annual Report and Share Option Scheme.

USE OF PROCEEDS

In addition to the information provided in the Annual Report, the board of directors (the "**Board**") wishes to provide the shareholders and potential investors of the Company with the following supplementary information (presented in italic and underline) in relation to the use of proceeds.

Use of proceeds from Listing

The table below sets out the proposed applications of the net proceeds from the Listing Date to 31 December 2025 and the date of this annual report:

Intended use of Net Proceeds	Original allocation HK$' million	Revised allocation as at 16 October 2020 HK$' million	Revised allocation as at 2 March 2021 HK$' million	*Utilisation of Net Proceeds during the Reporting Period HK$' million*	Utilised amount of Net Proceeds as at 31 December 2025 HK$' million	Unutilised amount of Net Proceeds as at 31 December 2025 HK$' million	Unutilised amount of Net Proceeds as at the date of Annual Report HK$' million	Expected timeline for fully utilising the Unutilised Net Proceeds
For partly financing the acquisition of an additional foreign worker dormitory at an estimated consideration of HK$162.0 million	77.1	61.3	46.6	*N/A*	46.6	–	–	N/A
For financing the acquisition of 10 additional lorries	5.5	3.7	3.7	*0*	1.8	1.9	1.9	By the end of December 2026
For financing the investment in securities	–	10.0	10.0	*N/A*	10.0	–	–	N/A
For repayment the loan	–	5.8	–	*N/A*	N/A	N/A	N/A	N/A
For injection of registered capital in Jinhai Medical	–	–	20.5	*N/A*	20.5	–	–	N/A
Total	82.6	80.8	80.8	*0.0*	78.9	1.9	1.9	

The unutilised proceeds from the Listing brought forward from 31 December 2024 was in the amount of HK$1.9 million.

Use of proceeds from Placings in October 2023

The table below sets out the proposed applications of the net proceeds from the date of completion to 31 December 2025 and the date of this annual report:

Intended use of Net Proceeds	Original allocation HK$' million	*Utilisation of Net Proceeds during the Reporting Period HK$' million*	Utilised amount of Net Proceeds as at 31 December 2025 HK$' million	Unutilised amount of Net Proceeds as at 31 December 2025 HK$' million	Unutilised amount of Net Proceeds as at the date of Annual Report HK$' million	Expected timeline for fully utilising the Unutilised Net Proceeds
For the expansion of business in the medical industry	69.0	*N/A*	69.0	–	–	N/A
For the expansion of business in manpower outsourcing and ancillary services	15.0	*0*	3.0	12.0	12.0	By the end of December 2026
For the general working capital of the Group	15.0	*N/A*	15.0	–	–	N/A
Total	99.0	*0.0*	87.0	12.0	12.0	

The unutilised proceeds from Placings in October 2023 brought forward from 31 December 2024 was in the amount of HK$12.0 million.

SHARE OPTION SCHEME

In addition to the information provided in the Annual Report, the Board wishes to provide the shareholders and potential investors of the Company with the following supplementary information (presented in italic and underline) in relation to the Share Option Scheme.

454,960,000 Shares are available for issue under the Share Option Scheme representing approximately 8.6% out of 5,290,000,000, being the total number of issued Shares as at 24 April 2026.

For details of the options granted under Share Option Scheme, please refer to the announcement of the Company dated 9 January 2024, the circular of the Company dated 29 January 2024 and the poll results announcement of the Company dated 19 February 2024.

For details of the share subdivision of the Company, please refer to the announcement of the Company date 1 November 2024, circular of the Company dated 22 November 2024 and the poll results announcement of the Company dated 10 December 2024.

The above supplementary information does not affect other information contained in the Annual Report. Save as disclosed above, all other information in the Annual Report remains unchanged.

By Order of the Board
Jinhai Medical Technology Limited
Chen Guobao
Chairman of the Board and executive Director

Hong Kong, 14 September 2026

As at the date of this announcement, the Board comprises eight Directors, of which four are executive Directors, namely Mr. Chen Guobao, Mr. Li Bin, Mr. Wang Zhenfei and Mr. Li Yunping; one is non-executive Director, namely Mr. Wang Huasheng; and three are independent non executive Directors, namely Mr. Yan Jianjun, Mr. Fan Yimin and Ms. Yang Meihua.